Further it has been shown that administration of anti-tumor immunotherapy specifically, peritoneal injection of toll like receptor 9 (TLR9) agonist CpG oligodeoxynucleotide combined with the TGF-β2 inhibitor TIO3 enhanced the presence of trogocytic neutrophils within the tumor nodules. This evidence concerns the gene TLR9 and neoplasm.